| About the author: |
Moiseeva N. V., Vakhnenko A. V., Rumyantseva M. A. |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
During recent decades have seen a dramatic increase of the number of patients with COPD. This pathology is becoming more substantial medical and social and economic values, and remains one of the major causes of morbidity and mortality worldwide. This is due to environmental pollution, especially air, smoking prevalence and population aging in all countries of the world. Distribution of underdiagnosis of COPD, inadequate antimicrobial therapy lead to increased incidence of complications of COPD and bronchoectasis. Among disadvantages focuses tobacco epidemic, which serves as a common risk factor for the development of not only diseases of the pulmonary system, and cardiovascular system. Significant relevance has polymorbidity, which is particularly characteristic of the older age groups. It is in the group of patients older than 40 years against the background of COPD, there is the rapid progress of CHD, which is one of the leading places in the structure of morbidity and mortality in Ukraine. In view of the high prevalence of CHD and a high probability of serious complications that cause disability and high fatality this problem, except medical, and pronounced social character. It is not difficult to suggest that during exacerbation of bronchoectasis complicated, against CHD requires a more balanced prescribing. And the question of conservative treatment of comorbid disease in the literature is given very few attention. That is why objective of this study was to identify ways to optimize the treatment of moderate-to-severe COPD exacerbations of bronchoectasis complicated for CHD. Previously found that the development and progression of COPD is accompanied by inhibition of the local immune defense system of the bronchial tree and impaired immunity. Among the major disorders of T-cell immunity in patients with COPD complicated bronchoectasis, against CHD can be isolated T-cell immunodeficiencies with predominantly T-helper or T-suppressor of immune deficiency. Identified types of immunological disorders is the basis for immunological correction Glutoxim which has immunomodulatory, bronchodilator, desensitizing, anti-inflammatory and antimicrobial action and is imunorehabilitator. The use of this drug was effective and improved immunological parameters in patients with impaired multivector cellular immunity. According to modern concepts, one of the leading roles in the onset and progression of cardiovascular disease, vascular endothelial dysfunction plays. Therefore, the decrease damage, correction and maintenance of an adequate functioning of the endothelium is one of the most urgent problems of modern therapy of vascular disease especially coronary heart disease. Therefore complement the standard combination therapy Glutoxim and L-arginine aspartate having detoxification activity, membrane stabilizing, antihypoxia, cytoprotective, anti-radical and anti-oxidant action and normalizes the function of the vascular endothelium, led not only to improved immune defense of the body, but also significantly improved the quality of all the parameters of life of patients. Improvement in these areas is beneficial not only to the quality of life of patients, but also for the establishment of compliance. Long-term monitoring of these patients showed a decrease in the number of exacerbations, possibly associated with improved stress tolerance of patients. |
| Tags |
сhronic obstructive pulmonary disease, bronchoectasis |
| Bibliography |
- Gembickaja T. E. Klinicheskie osobennosti, diagnostika i lechenie nekotoryh nasledstvenno obuslovlennyh zabolevanij organov dyhanija u vzroslyh: Dis. dokt. med. nauk: 14.00.43/ Vsesojuzn. NII pul'monologii / T.E. Gembickaja. - Leningrad, - 1987. - 158 s.
- Dvoreckij L. I. Infekcija i hronicheskaja obstruktivnaja bolezn' legkih / L. I. Dvoreckij // Consilium Medicum. - 2001. - №3(12). - S. 587-595.
- Dzjublik A. Ja. Obostrenie HOZL: sovremennoe sostojanie problemy / A. Ja.Dzjublik, T. A. Perceva // Ukr. pul'monol zhurn. - 2009. - №2. - 10 s.
- Djachenko V. V. Mesto peroral'nyh cefalosporinov IIIpokolenija v lechenii infekcij dyhatel'nyh putej / V. V. Djachenko // Terapia. Ukraїns'kij medichnij vіsnik. - 2010. - №10. - S. 40-42.
- Іl'nic'kij R. І. Osoblivostі іmunologіchnoї reaktivnostі u hvorih na hronіchne obstruktivne zahvorjuvannja legen' / R. І. Іl'nic'kij // Ukr. pul'monol. zhurn. - 2007. - №2(56). - S. 21-25.
- Zin'kovskij M. F. Oksid azota i legochnaja gipertenzija/M.F.Zin'kovskij // Zdorov'e Ukrainy.-2008-№13-14,62 s.
- Kopeljan I.I. Razrabotka mikromodifikacii kul'tivirovanija kletok krovi / I.I. Kopeljan, M.P. Grigor'eva // Bjull. jeksp. biol. i med. - 1972. - №9. - S 119-122.
- Konopleva L. F. Ocenka jeffektivnosti primenenija L-arginina pri legochnoj arterial'noj gipertenzii razlichnogo ґeneza / L. F. Konopleva, L. V. Kushnir // Ukr. med. chasopis. - 2013. - №1(93). - S. 115-119.
- Leshhenko I. V. Osnovnye napravlenija lechenija hronicheskoj obstruktivnoj bolezni legkih / I. V. Leshhenko // Ter. Arhiv. - 2007. - №5. - S. 75-84.
- Molodcova A.V. Ocenka jeffektivnosti immunomoduljatora Glutoksima v lechenii bol'nyh hronicheskimi obstruktivnimi zabolevanijami legkih: avtoref dis. kand. med. nauk: 14.00.43 / A.V. Molodcova. - SPb, - 2005. -23 s.
- Ostrovs'kij M. M. Optimіzacіja korekcії bronhіal'noї obstrukcії pri zagostrennі hronіchnogo obstruktivnogo zahvorjuvannja legen' / M. M. Ostrovs'kij // Zdorov’ja Ukraїni: Tematichnij nomer. - 2011. - №4(16). - S. 12-14.
- Perederij V. G. Immunnyj status, principy ego ocenki i korrekcii immunnyh narushenij / V. G. Perederij, A.M. Zemskov, N.G. Bychkov [i dr.] // - K.: Zdorov'ja, - 1995. - 211 s.
- Soodaeva S.K. Oksidantnaja i antioksidantnaja sistemy pri hronicheskih obstruktivnih zabolevanijah legkih. Hronicheskie obstruktivne bolezni legkih / S.K. Soodaeva // - SPb.: Nevskij dіalekt, - 1998. - S. 92-111.
- Feshhenko Ju. I. Obstruktivnye zabolevanija legkih / Ju. I. Feshhenko, L. A. Jashina, A. M. Poljanskaja [i dr.]. // - Kiїv, - 2004. - 287 s.
- Feshhenko Ju. I. Kontrol' nad HOZL – vozmozhen li on segodnja? / Ju.I. Feshhenko // Zdorov’ja Ukraїni. - Tematichnij nomer. - 2011. - №1. - S. 1-3.
- Feshhenko Ju. I. Novaja redakcija rukovodstva Global'noj iniciativy po obstruktivnomu zabolevaniju legkih (GOLD) / Ju.I. Feshhenko // Zdorov’ja Ukraїni. - Tematichnij nomer. - 2012. - №2(18). - S. 10-11.
- Buch P. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study / P. Buch, J. Friberg, H. Scharling [et al.] // Eur. Respir. J., Vol. 21(6), - 2003, P.1012-1016.
- Dankner R. Predictors of cardiac and noncardiac mortality among 14,697 patients with coronary heart disease / R. Dankner, U. Goldbourt, V. Boyko [et al.] // Am. J. Cardiol., Vol.91(2), - 2003, P. 121-127.
- Global initiative for chronic obstructive lung gisease. WHO, updated 2011.
- Haskova V. Simpl method of circulating immune complex defection in human sera be polyethylenglycol precipitation / V. Haskova // Immunol. Forsch. - 1977. - №4. - Р. 399-486.
- Herper-Owen R. Virus and chlamidia isolation in COPD exacerbation / R. Herper-Owen // Eur. Resp. J. - Vol. 14, Suppl. 30, Oct. - 1999 - 392 p.
- Mancini G. Immunochemical quantitation of antigens by single radial immuno diffusion / G. Mancini, A.O. Carbonara, J.F. Heremans // Immuno chemistry. - 1965. - Vol. 2. - P. 235-254.
- Ozaras R. Changes in malondialdehyde levels in bronchoalveolar fluid and serum by the treatmentof asthma with inhaled steroid and beta 2 agonist / R. Ozaras, V. Tahan, F. Talay [et al.] // Respiratory - 2000. - Vol. 5, №3. - Р. 289-292.
- Rabe K. F. Roflumilast for the treatment of chronic obstructive pulmonary disease / K.F. Rabe // Expert Rev Resp Med. - 2010. - Vol. 4. - Р. 543-555.
- Tager M. Evidense of a defective thiol status of alveolar macrophages from COPD patients and smokers. COPD / M. Tager, A. Biecyk, T. Kohnelin [et al.] // Free Radic. Biol. Med. - 2000. - Vol. 29, №11. - Р.1160-1165.
|
| Publication of the article |
«World of Medicine and Biology» №2(49) 1 part 2015 year, 048-055 pages, index UDK 616.23/.24+616.12/.14] – 002 – 008 |
